(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling ...

The CGM study aims to find out what normally glucose levels are ... research in Bristol hears the voices of all women living in the Bristol area. MAP A Co-design Study MAP A Co-design project is being ...

Diabetes device expert Steph Habif said her family's experiment with CGMs shows a big opportunity for wearables: intermittent ...

The use of a continuous glucose monitor during pregnancy may be more cost-effective than self-monitoring blood glucose for ...

By utilizing advanced machine learning techniques, researchers were able to simulate CGM data for each participant throughout the trial. According to UVA Health, the study found that the amount of ...

RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design ... study, marking a significant ...

announced the successful completion of its first in human clinical study, marking a significant milestone in continuous glucose monitoring. This study represents the first real-time, continuous ...